Older Melanoma Patients Get Different Treatments—But Outcomes Are Just as Good

Older melanoma patients receive fewer rounds of treatment and different drug combinations than younger patients, but their survival outcomes are remarkably similar, according to a large real-world study of over 8,200 patients. This finding challenges assumptions that age alone should limit treatment intensity for skin cancer.

Researchers analyzed data from the ADOREG registry, a multicenter database tracking melanoma patients treated at skin cancer centers across Germany between 2013 and 2023. The study included 8,213 patients with a median age of 64 years, with about 26% aged 75 or older. Of these patients, 3,646 had melanoma that had spread to other parts of the body (metastatic disease).

Why Do Doctors Treat Older and Younger Melanoma Patients Differently?

The research revealed clear differences in how treatment was approached based on age. Older patients received fewer lines of therapy overall—an average of 1.60 treatment rounds compared to 2.08 for younger patients. They were also less likely to receive surgery, radiation therapy, or systemic medications like immunotherapy drugs.

Additionally, younger patients more frequently received combination immunotherapy treatments (multiple drugs working together), while older patients were more likely to receive single-agent immune checkpoint inhibitor (ICI) therapy, which targets specific proteins that help cancer hide from the immune system. Despite these differences in treatment patterns, the actual effectiveness of the drugs was nearly identical across age groups.

Do Age-Based Treatment Differences Actually Affect Survival?

This is where the findings become particularly encouraging. When researchers measured how well first-line treatments worked—meaning the initial therapy patients received—they found virtually no difference between age groups. The overall response rate (the percentage of patients whose tumors shrank or disappeared) was 30.5% for patients under 75 years old and 30.4% for those 75 and older.

The disease control rate, which measures how many patients experienced either tumor shrinkage or stable disease without progression, was 43.9% for younger patients and 48.8% for older patients. When looking specifically at immunotherapy effectiveness, the response rates were 28.2% for younger patients and 30.4% for older patients—again, showing no meaningful difference.

"Age influenced treatment selection in melanoma patients. However, in geriatric patients, efficacy was not impaired, and a balanced toxicity profile was noticed, particularly for immunotherapy," the researchers concluded. This suggests that the differences in treatment approach may reflect physician caution rather than actual medical necessity.

How to Advocate for Appropriate Melanoma Treatment at Any Age

• Discuss biological age, not calendar age: Ask your oncologist to evaluate your overall health, fitness level, and ability to tolerate treatment rather than making decisions based solely on your birth year. The study emphasized that "biological age and impairment by comorbidities" should guide individualized treatment decisions.
• Ask about combination immunotherapy options: If you're an older patient, inquire whether combination immune checkpoint inhibitor therapy might be appropriate for your specific situation, rather than assuming single-agent treatment is your only option.
• Seek a second opinion from a melanoma specialist: Because older patients are historically underrepresented in clinical trials, some oncologists may have less experience treating them aggressively. A specialist in melanoma care may offer different perspectives on your treatment options.
• Request a toxicity assessment: Interestingly, younger patients actually experienced more immune-related side effects (49.7%) compared to older patients (42.5%), suggesting that age alone doesn't predict who will tolerate immunotherapy well.

What Does This Mean for the Future of Melanoma Care?

The study highlights an important gap in cancer care: older adults are often excluded from clinical trials, leaving doctors with limited evidence to guide treatment decisions. As melanoma incidence increases significantly with age, this knowledge gap affects a growing number of patients. The researchers called for future studies that consider individual health status rather than age as the primary factor in treatment planning.

Beyond the clinical data, it's important to recognize that a melanoma diagnosis carries emotional weight at any age. The psychological impact of cancer—identity shifts, trauma, and the nonlinear healing process—deserves attention alongside medical treatment. "There is no correct timeline. No perfect emotional response. No single way to move through this," according to perspectives shared by cancer care experts. Support resources, including peer mentorship and counseling, can be as valuable as the medications themselves.

For older patients newly diagnosed with melanoma, this research offers reassurance: your age should not automatically limit your treatment options or your chances of a good outcome. The key is finding an oncologist willing to evaluate your individual health status and discuss all available options, rather than making assumptions based on age alone.